Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform…

Overview of attention for article published in Frontiers in Pharmacology, July 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter: 2 X users

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Wikipedia Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,193 followers.

RT @FrontPharmacol: New Research: Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer fr…

20 Jul 2023

Reply Repost Favourite

New Research: Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing #pharmacology https://t.co/ocV

20 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.